| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
| ln Vitro |
Fasentin (0.1-1000 μM; 72 hours) inhibits the growth of endothelial cells, tumors, and fibroblasts without causing cell death [1]. Fasentin (25-100 μM; 16-24 hours) induces cell cycle arrest in the G0/G1 phase and decreases the number of S-phase cells in a dose-dependent manner [1]. Fasentin (50 μM; 16 hours) modifies the expression of genes linked to glucose deprivation, such as AspSyn and PCK-2[2]. Fasentin (15, 30, 80 μM; 1 hour pretreatment) induces glucose deprivation and partially blocks glucose uptake in PPC-1, DU145, and U937 cells [2]. Fasentin (100 μM; 16 hours) has no effect on endothelial cell migration [1]. Fasentin (25–100 μM; 16 hours) decreased phospho-ERK levels in HMEC, indicating partial inhibition of the ERK signaling pathway, though the effect was not statistically significant.
|
|---|---|
| Cell Assay |
Cell viability assay [1]
Cell Types: three endothelial cell ECs (HMEC, human microvascular endothelial cells; HUVEC, human umbilical vein endothelial cells; and BAEC, bovine aortic endothelial cells), three human tumor cell lines (MDA-MB - 231 and MCF7 breast cancer cells, HeLa cervical adenocarcinoma cells) and human gingival fibroblasts (HGF) Tested Concentrations: 0.1, 1, 10, 100, 1000 μM Incubation Duration: 72 hrs (hours) Experimental Results: Inhibition of endothelial cells, tumors and fibroblasts cell growth (IC50 =26.3-111.2 μM) and does not induce cell death. Cell cycle analysis [1] Cell Types: HMEC Tested Concentrations: 25, 50, 100 μM Incubation Duration: 16, 24 hrs (hours) Experimental Results: Induced cell cycle arrest in G0/G1 phase and diminished the number of S phase cells in a dose-dependent manner. There was no increase in the subG1 population. RT-PCR[2] Cell Types: PPC-1 cells[2] Tested Concentrations: 50 μM Incubation Duration: 16 hrs (hours) Experimental Results: Altered expression of genes associated with glucose deprivation such as AspSyn and PCK-2 not FLIP mRNA expression. |
| References |
|
| Molecular Formula |
C11H9CLF3NO2
|
|---|---|
| Molecular Weight |
279.642872571945
|
| Exact Mass |
279.027
|
| CAS # |
392721-37-8
|
| PubChem CID |
879520
|
| Appearance |
Light yellow to brown ointment
|
| Melting Point |
141.7 °C
|
| LogP |
3.925
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
18
|
| Complexity |
333
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(CC(NC1=CC(C(F)(F)F)=C(Cl)C=C1)=O)=O
|
| InChi Key |
GNYIJZMBLZXJEJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H9ClF3NO2/c1-6(17)4-10(18)16-7-2-3-9(12)8(5-7)11(13,14)15/h2-3,5H,4H2,1H3,(H,16,18)
|
| Chemical Name |
N-[4-chloro-3-(trifluoromethyl)phenyl]-3-oxobutanamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~357.60 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.94 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (8.94 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.94 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5760 mL | 17.8801 mL | 35.7603 mL | |
| 5 mM | 0.7152 mL | 3.5760 mL | 7.1521 mL | |
| 10 mM | 0.3576 mL | 1.7880 mL | 3.5760 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
